Study of mirivadelgat for pulmonary hypertension with interstitial lung disease
Part of Lungs & breathing clinical trials.
This study tests a new medication called mirivadelgat for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The goal is to see if it can help improve symptoms and slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You need a confirmed diagnosis of interstitial lung disease, seen on a CT scan or lung biopsy.
- You must have had a right heart catheterization (a test that measures pressures in your heart and lungs) showing high pressures and resistance.
- You must be able to walk at least 100 meters but no more than 500 meters in six minutes.
- You must not be on certain other PH medications (like riociguat or bosentan) within the last 60 days.
- You must not have had a recent flare-up of your lung disease or a respiratory infection in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called NS-863 for people with pulmonary hypertension (high blood pressure in the lungs) that is caused by interstitial lung disease (scarring of the lungs). The study will check if the drug is safe and effective in improving your condition.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
Hear when a new Group 3 Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.